Retatrutide vs. Tirzepatide: Is Retatrutide Actually Available in 2026?

Is retatrutide actually available right now?

No. Retatrutide has not received FDA approval for any indication as of September 2026. It's a real drug with real trial data behind it — not vaporware — but "in late-stage trials" and "available" are two different things, and the search volume around it has outrun the regulatory reality by a wide margin.

Eli Lilly has completed the core of its TRIUMPH Phase 3 program, the trials that would normally support an approval application, and has said publicly it intends to file with the FDA in the first quarter of 2027. Part of what's driving that timeline is a classification question: whether retatrutide gets reviewed as a biologic (Biologics License Application, with longer market exclusivity) or as a conventional drug (New Drug Application). That distinction turns on FDA rules about how a peptide is made and how large it is — it's a real regulatory fork in the road for a molecule like this, and it affects both the filing pathway and the timeline.

None of that changes the practical answer for a woman deciding what to do this month: even under an optimistic reading of Lilly's own timeline, a Q1 2027 filing means standard FDA review time still has to run its course before any approval, which puts realistic commercial availability into late 2027 at the earliest, and plausibly into 2028. Filing dates for drugs this complex have moved before, so treat any specific month as directional, not a promise.

What you're actually buying if you order "retatrutide" online today

Here is the part that matters most if you've already found a website selling it: nothing being sold online right now as "retatrutide" is a legitimate compounded drug, and none of it comes from a licensed pharmacy operating within the law. This isn't a gray area the way some compounded semaglutide or tirzepatide questions are — the FDA has said so in writing.

In a letter to state pharmacy boards, the FDA's Office of Compounding Quality and Compliance laid out the specific legal test: a pharmacy can only compound with a bulk drug substance if it's listed in an official USP/NF monograph, is already a component of an FDA-approved drug, or appears on the FDA's published bulk-substance lists for 503A or 503B pharmacies. Retatrutide meets none of those three conditions. The letter's conclusion is unambiguous: compounded retatrutide products don't qualify for the legal exemptions that let compounding pharmacies operate at all, under either 503A or 503B. The Alliance for Pharmacy Compounding — the trade group representing compounding pharmacists — has told its own members not to compound it.

So what is actually shipping when someone orders "retatrutide" online? Products sold through research-chemical marketplaces, typically labeled "for research purposes only" or "not for human consumption" — language that exists specifically to sidestep FDA drug regulations, not because the seller expects it to sit in a lab freezer. The FDA has already acted against sellers doing exactly this — warning letters over retatrutide and similar peptides sold direct to consumers with per-week dosing instructions and bacteriostatic water marketed alongside it as an injection diluent, the kind of detail that only makes sense if the buyer is injecting it, not researching it in a lab.

• There is no clinician reviewing your dose, your health history, or your labs before the product ships — you're placing an order, not getting a prescription.
• There is no named, licensed 503A or 503B pharmacy behind the product, because none can legally exist for this substance right now.
• There's no independent verification of what's actually in the vial — purity, sterility, and concentration are whatever the seller claims, with none of the manufacturing oversight that applies to an FDA-approved or even a legally compounded drug.
• Reported prices across these marketplaces are all over the place — roughly $50 to a few hundred dollars per vial depending on the site, working out to anywhere from about $150 to $500-plus a month for a typical protocol dose — and that inconsistency is itself a signal there's no real pharmacy pricing standard behind any of it.

For a fuller picture of what a legitimate compounding pathway does and doesn't allow — the kind that genuinely exists for tirzepatide right now — see compounded tirzepatide, which walks through the 503A individual-patient rules that retatrutide currently fails to meet.

What the trials actually show: does retatrutide outperform tirzepatide?

The trial data is genuinely impressive, and it's worth taking seriously even while the access question stays unresolved. Retatrutide is a triple agonist — it activates receptors for GIP, GLP-1, and glucagon, where tirzepatide activates only the first two. Lilly's TRIUMPH program ran four pivotal Phase 3 trials across different populations. In TRIUMPH-1 — adults with obesity or overweight and at least one weight-related condition, without diabetes — participants on the highest studied dose (12mg) lost an average of 28.3% of body weight at 80 weeks and 30.3% at 104 weeks, a level of loss that starts to approach what's typically seen after bariatric surgery. In TRIUMPH-2, which enrolled people with type 2 diabetes and obesity, average loss at 80 weeks ran closer to 21%. TRIUMPH-3, in people with obesity and established cardiovascular disease, showed up to roughly 22.6% loss (about 55.8 lbs) at 80 weeks. TRIUMPH-4, in people with obesity and knee osteoarthritis, reported weight loss alongside a meaningful reduction in knee pain.

Compare that to tirzepatide's own SURMOUNT trial series, which supported Zepbound's approval: average weight loss there ran roughly 15% to 22% of body weight over 72 weeks, depending on the trial and dose. On paper, retatrutide's numbers sit above tirzepatide's, and the gap is large enough that obesity-medicine researchers have taken real notice.

The catch is that none of those numbers come from a trial that put the two drugs head-to-head in the same participants. They're separate trials, in overlapping but not identical populations, run over slightly different timeframes — which makes any straight subtraction ("retatrutide is 8 points better") a reasonable-sounding but not fully earned conclusion. Lilly is running exactly that head-to-head comparison now, a trial called TRIUMPH-5, directly comparing retatrutide against tirzepatide in adults with obesity. It hasn't reported results as of this writing. Until it does, the honest version of "does retatrutide outperform tirzepatide" is: probably, based on separate trials that point the same direction, but not yet proven by the one study designed to actually answer the question.

Retatrutide vs. tirzepatide: real prices, side by side, today

Because retatrutide has no legal purchase pathway, there's genuinely nothing legitimate to put in a price comparison table next to it — the honest table has one side filled in. What follows are tirzepatide's real, current prices across the main pathways, so you can see exactly what "getting the real thing today" costs while retatrutide remains unavailable.

Curex currently has the lowest verified all-in price for compounded tirzepatide, with no separate membership fee layered on top — that $199 figure is a starter-dose rate, so ask for the maintenance-dose ladder before enrolling. LillyDirect's self-pay Zepbound program is the closest FDA-approved equivalent, starting at $299 a month for the 2.5mg dose and topping out at a flat $449 from 7.5mg through 15mg, as long as you refill within its 45-day window. Mochi Health, Henry Meds, and Willow round out the compounded field with different tradeoffs — Mochi's medication price now varies by dose since an August 2026 pricing change, Henry Meds is one of the only providers with an oral tablet, and Willow's price climbs with dose but covers roughly 33 states. Retail without any of that — a standard pharmacy fill with a GoodRx coupon and no self-pay program — runs nearly three times LillyDirect's ceiling.

For the complete breakdown of every compounded tirzepatide provider we track, including several not featured above, see compounded tirzepatide. For every brand and cash-pay pathway side by side, see tirzepatide cost, and for the full Zepbound-specific comparison this page draws from, see Zepbound vs. tirzepatide.

Side effects and safety: does a third receptor change the risk profile?

Adding glucagon receptor activity is retatrutide's whole pitch — glucagon signaling raises resting energy expenditure, which is part of why the weight-loss numbers run higher — but it isn't free. The most consistent difference in the trial data so far is a modest uptick in heart-rate-related effects: reports of palpitations or irregular heartbeat sensations ranged from roughly 2% to 11% of retatrutide participants across the Phase 2 and Phase 3 program, versus about 2% on placebo, trending higher at higher doses. None have been classified as serious, and Lilly hasn't reported an increase in major cardiac events like heart attack or stroke across the program so far — but "so far" is doing real work in that sentence, because this is trial-phase safety data, not the years of real-world postmarket surveillance tirzepatide already has behind it.

Gastrointestinal side effects look broadly similar in kind to tirzepatide's — nausea, diarrhea, constipation, vomiting — but ran somewhat higher in TRIUMPH-1's highest studied dose. Nausea was reported by 28.6% to 42.4% of retatrutide participants depending on dose, compared with 14.8% on placebo, and discontinuation specifically due to adverse events reached 11.3% at the top dose versus 4.9% on placebo. Tirzepatide's own SURMOUNT-1 trial reported nausea around 31% overall and discontinuation-for-adverse-events between 4.3% and 7.1% across its dose range, topping out at 6.2% at the approved 15mg dose. Again — different trials, different populations, not a head-to-head — but the pattern across both readings is that a third receptor target may come with a somewhat steeper tolerability tradeoff for the strongest results, not a free upgrade.

When might retatrutide actually get FDA approved — is it worth waiting for?

This is the most volatile section on this page, and it deserves to be read with that caveat front and center. Lilly's own stated target is a first-quarter-2027 filing, contingent on resolving the classification question above and finishing the manufacturing and quality-control data the FDA has asked for. Filing is not approval: standard FDA review typically runs months beyond a completed filing, which is why realistic commercial availability lands more plausibly in late 2027 or into 2028 even if nothing else slips. Companies developing drugs this complex have pushed dates before, in both directions, so treat any specific month you read — on this page or elsewhere — as a snapshot of a moving target, not a locked-in date.

Whether it's "worth waiting for" depends entirely on what you're solving for. If the goal is the single strongest possible average weight-loss number and you're willing to hold off treatment for a year or more with no medication in the meantime, retatrutide's trial data is genuinely compelling. If the goal is treating perimenopausal or menopausal weight change now — while it's actively affecting your metabolic health, not hypothetically in 2027 — tirzepatide is the real option sitting in front of you today, approved, priced, and available through the pathways above.

Who should just get tirzepatide now, and who might reasonably wait

• You want a real, legal, prescription-grade GLP-1 medication this month → tirzepatide, full stop. It's the only one of the two molecules you can currently obtain through any legitimate pathway, compounded or brand-name.
• You've read retatrutide's trial numbers and want the strongest possible result → understand that no amount of money buys you legal access to it right now; the data is real, the product isn't purchasable.
• You're tempted to "wait it out" rather than start tirzepatide → do the math on the wait itself. Lilly's own Q1 2027 filing target plus standard review time points to late 2027 or 2028 at the earliest — many more months of untreated weight and metabolic changes during perimenopause, a window when that has real consequences.
• You're eyeing a "research peptide" seller because it looks cheap → the FDA has explicitly said no U.S. pharmacy can legally compound retatrutide right now, and it's issuing warning letters against sellers well into 2026. There's no clinician behind the dose and no verified quality standard behind the vial.
• You're already on compounded or brand-name tirzepatide and it's working → there's no clinical reason to switch based on retatrutide's data alone. It hasn't been tested head-to-head against tirzepatide yet — that's exactly what the ongoing TRIUMPH-5 trial is for — so you'd be trading a working, legal treatment for something that doesn't exist as a product yet.

Red flags when anything online claims to sell retatrutide

• A "research use only" or "not for human consumption" label sitting next to per-week dosing charts, injection-volume instructions, or bacteriostatic water sold as a diluent — a real research reagent doesn't need any of that.
• No intake form, health history review, or clinician sign-off before you can check out — an add-to-cart button standing in for a prescription.
• No named, licensed pharmacy behind the product — and there legally can't be one for retatrutide right now, so a seller that claims otherwise is either mistaken or not being straight with you.
• A marketplace or storefront format rather than a telehealth platform with a named medical group you can actually verify.
• No lot-level purity, sterility, or concentration testing disclosed anywhere on the site.
• No way to reach a clinician if you have a reaction — check for a real support line before you check for a discount code.
• The FDA has already issued warning letters against specific retatrutide sellers in 2026 — active enforcement, not a hypothetical risk.